Form 4: Ligand CFO Acquires Stock via Employee Purchase Plan

Ligand Pharmaceuticals CFO Octavio Espinoza acquired 8 shares of common stock through the company's Employee Stock Purchase Plan at $95.676 per share.

Summary

• Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc. (LGND), acquired 8 shares of common stock.
• The transaction occurred on December 31, 2025, at a price of $95.676 per share.
• These shares were acquired under the Ligand Employee Stock Purchase Plan (ESPP).
• The acquisition is exempt under SEC Rules 16b-3(d) and 16b-3(c).
• Following this transaction, Mr. Espinoza directly beneficially owns 28,575 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive due to an insider acquiring shares, indicating confidence. However, the small number of shares acquired through a routine ESPP limits the overall impact on sentiment.

Positives

• An insider, the Chief Financial Officer, acquired additional shares in the company, which can signal confidence in the company's future prospects.
• The acquisition was made through a standard Employee Stock Purchase Plan, indicating participation in a broad-based employee benefit program.

Future Outlook

NA

Industry Context

Insider transactions, such as those reported on Form 4, are routinely monitored by investors for signals regarding management's confidence in their company's performance and future outlook. Employee Stock Purchase Plans are common mechanisms for employees to acquire company stock.

Related Party Transactions

• Acquisition of common stock by the Chief Financial Officer through the company's Employee Stock Purchase Plan.

Stakeholder Impact

• Shareholders may view the CFO's stock acquisition as a minor positive signal of management's alignment with shareholder interests and confidence in the company.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Octavio Espinoza, CFO, Insider Transaction, Form 4, Stock Acquisition, ESPP, Employee Stock Purchase Plan